It is well known that
Alzheimer's disease (AD) is closely related to
diabetes mellitus (DM), and AD is also regarded as Type 3 diabetes (T3D). However, the exact link between AD and DM is still unclear. Recently, more and more evidence has shown that
glycogen synthase kinase-3β (GSK-3β) may be the potential link between DM and AD. In DM, GSK-3β is the crucial
enzyme of
glycogen synthesis, which plays a key role in regulating
blood glucose. More importantly, GSK-3β is one of the key factors leading to
insulin deficiency and
insulin resistance, and
insulin resistance is an important hallmark of the occurrence and development of DM. In AD, GSK-3β plays an important role in hyperphosphorylation of
microtubule-associated protein tau (tau), which is one of the pathological features in AD. GSK-3β is one of the important
kinases of tau phosphorylation and is involved in the
insulin/
phosphoinositide 3-kinase/
protein kinase B (
insulin/PI3K/Akt) signaling pathway. Dysfunction of the
insulin/PI3K/Akt signaling pathway, which regulates
glucose metabolism in the brain, can lead to tau hyperphosphorylation in the brain of AD patents. Additionally,
insulin resistance in DM may cause β-
amyloid (Aβ) deposition, which will be cleared by tau, but excessive phosphorylation of tau will further aggravate the neurotoxicity; then damage the brain and affect the cognitive function. GSK-3β is considered as a common
kinase in
insulin signaling transduction and
tau protein phosphorylation, so we have reasons to believe that GSK-3β is a potential link between DM and AD.